About

Mobius Therapeutics is an early stage venture focused on ophthalmic surgery solutions.  Its first product, Mitosol®, is a system for delivering antifibrotic agents in glaucoma, refractive, and corneal surgery.  The glaucoma indication is in active commercialization; the refractive and corneal indications are awaiting approval by the Food and Drug Administration.